Genmab — November 2019
-
Lidt Ofa: HCVAD-O is a safe and highly effective regimen in pts with CD20+ Ph-negative B-ALL. This regimen achieves excellent outcomes in the AYA population (...) All but 1 pt (98%) achieved CR (2 after 2 cycles)...Using historical control pts, there was a trend towards improved OS with HCVAD-O versus HCVAD-R
-
The preliminary analysis of the GELLC7 trial showed that the addition of consolidation with ofatumumab after 12 cycles of prior treatment with ibrutinib was well tolerated and elicited a deeper response.(...)In 20 patients receiving the consolidation with ofatumumab an improvement in response was observed, with 8/20 patients (40%) attaining a CR (7 patients converted PR to CR, and one patient SD to CR
-
862 Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple Myeloma: A Clinical and Correlative Phase 2 Study https://ash.confex.com/ash/2019/webprogram/Paper126378.html
-
695 Efficacy and Tolerability of (Ixa Dara dex) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; Results of the Interim Efficacy Analysis of the Phase II HOVON 143 Study https://ash.confex.com/ash/2019/webprogram/Paper121694.html
-
from
Luciano J Costa
@End_myeloma
https://ash.confex.com/ash/2019/webprogram/Paper123401.html
This is big news. I honestly can't think of any other intervention in MM with this much impact in survival. Congratulations to the Alcyone team
@mvmateos
#ASH2019 #mmsm
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind